Loading ETF profile…
The First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund (ETF) designed with a clear purpose: to accurately reflect the price movements and income generated by the NYSE Arca Biotechnology Index. Its core objective is to closely match the performance of this benchmark index, before accounting for the fund's operational fees and expenses.
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| CORT | Corcept Therapeutics Inc. | 5.53% | $147.18M |
| VCYT | Veracyte, Inc. | 5.02% | $133.65M |
| NEO | NeoGenomics, Inc. | 4.33% | $115.22M |
| BRKR | Bruker Corporation | 4.25% | $113.25M |
| ALKS | Alkermes Plc | 4.18% | $111.31M |
| ILMN | Illumina, Inc. | 3.96% | $105.35M |
| AXSM | Axsome Therapeutics, Inc. | 3.94% | $104.94M |
| KRYS | Krystal Biotech, Inc. | 3.81% | $101.47M |
| NBIX | Neurocrine Biosciences, Inc. | 3.63% | $96.75M |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 3.56% | $94.75M |
| NTRA | Natera, Inc. | 3.53% | $93.95M |
| EXEL | Exelixis, Inc. | 3.36% | $89.58M |
| BIIB | Biogen Inc. | 3.31% | $88.06M |
| INCY | Incyte Corporation | 3.15% | $83.95M |
| VRTX | Vertex Pharmaceuticals Incorporated | 3.12% | $82.94M |
| ARGX | argenx SE (ADR) | 3.10% | $82.44M |
| RGEN | Repligen Corporation | 3.05% | $81.28M |
| BMRN | BioMarin Pharmaceutical Inc. | 3.01% | $80.04M |
| HALO | Halozyme Therapeutics, Inc. | 2.98% | $79.30M |
| TECH | Bio-Techne Corporation | 2.94% | $78.25M |
| AMGN | Amgen Inc. | 2.87% | $76.37M |
| UTHR | United Therapeutics Corporation | 2.76% | $73.55M |
| BNTX | BioNTech SE (ADR) | 2.75% | $73.30M |
| GMAB | Genmab A/S (ADR) | 2.66% | $70.93M |
| GILD | Gilead Sciences, Inc. | 2.61% | $69.48M |